North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

More tepid economic news and a pledge by Donald Trump to push through tariffs on top trading partners stressed Wall Street ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

A rebound in stocks sputtered as data showed US manufacturing approached stagnation amid jump in prices, deepening concerns about the outlook for the world’s largest economy.

Police are holding two more suspects over the murder of a Scottish businessman in Kenya. Campbell Scott's body was found tied up in a sack of pineapples in a forest 60 miles (96.5km) from Nairobi, ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.